API




Key Events

Id Title Short name Biological organization
1252 Binding to (interferes with) topoisomerase II enzyme Binding, topoisomerase II Molecular
1094 , hyperuricemia , hyperuricemia
1027 , Learning and memory, impairment , Learning and memory, impairment
987 , Metaplasia of goblet cells , Metaplasia of goblet cells
1387 7α-hydroxypregnenolone synthesis in the brain, decreased 7α-hydroxypregnenolone synthesis in the brain, decreased Cellular
382 Aberrant, Dendritic morphology Aberrant, Dendritic morphology Cellular
560 Abnormal, Foraging activity and behavior Abnormal, Foraging activity and behavior Individual
183 Abnormal, Morphogenesis Abnormal, Morphogenesis
1108 Abnormal, Role change within caste Abnormal, Role change within caste Population
564 Abnormal, Roll change within caste Abnormal, Roll change within caste Population
535 Abnormal, Sperm penetration (polyspermy) Abnormal, Sperm penetration (polyspermy) Cellular
571 Accelerated, Aging Accelerated, Aging Individual
10 Accumulation, Acetylcholine in synapses Accumulation, Acetylcholine in synapses Cellular
46 Accumulation, Biological membranes Accumulation, Biological membranes Cellular
68 Accumulation, Collagen Accumulation, Collagen Tissue
570 Accumulation, Damaged mitochondrial DNA Accumulation, Damaged mitochondrial DNA Cellular
327 Accumulation, Fatty acid Accumulation, Fatty acid Organ
846 Accumulation, Highly carboxylated porphyrins Accumulation, Highly carboxylated porphyrins Organ
455 Accumulation, Liver lipid Accumulation, Liver lipid Organ
291 Accumulation, Triglyceride Accumulation, Triglyceride Cellular
1340 Activate, calmodulin Activate, calmodulin Molecular
1359 Activate, GABA-A receptor Activate, GABA-A receptor Molecular
1379 Activate, leukocyte Activate, leukocyte Cellular
1380 Activate, mucosal defense Activate, mucosal defense Tissue
1383 Activate, phospholipase Activate, phospholipase Molecular
1337 Activate, PLC (Phospholipase C) Activate, PLC Molecular
1360 Activate, presynaptic neuron 2 Activate, presynaptic neuron 2 Molecular
1385 Activated, gastric ulcer formation Activated, gastric ulcer formation Organ
1421 Activated, LXR Activated, LXR Molecular
1355 Activated, membrane depolarization Activated, membrane depolarization Cellular
1351 Activated, NMDA receptor Activated, NMDA receptor Molecular
1349 Activated, presynaptic neuron 1 Activated, presynaptic neuron 1 Molecular
1352 Activated, voltage-gated sodium channel Activated, voltage-gated sodium channel Molecular
1448 activation of CCAAT/enhancer-binding protein alpha activation of CEBPA Molecular
1391 Activation of Cyp2E1 Activation of Cyp2E1 Molecular
1507 Activation of PPARγ Activation of PPARγ Molecular
1028 Activation of specific nuclear receptors, PPAR-gamma activation Activation of specific nuclear receptors, PPAR-gamma activation Molecular
288 Activation of specific nuclear receptors, Transcriptional change Activation of specific nuclear receptors, Transcriptional change Cellular
1271 Activation of TGF-β signaling Activation of TGF-β signaling Cellular
1499 Increased, activation of T (T) helper (h) type 2 cells Activation of Th2 cells Tissue
1288 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Cellular
1336 Activation, 5-HT2A (Serotonin 2A) Activation, 5-HT2A Molecular
9 Activation, 5HT2c Activation, 5HT2c Molecular
18 Activation, AhR Activation, AhR Molecular
1299 Activation, AKT Activation, AKT Molecular
484 Activation, AKT2 Activation, AKT2 Molecular
785 Activation, Androgen receptor Activation, Androgen receptor Molecular
1309 Activation, aPKC Activation, aPKC Molecular
1038 Activation, beta-2 adrenergic receptor Activation, beta-2 adrenergic receptor Molecular
66 Activation, ChREBP Activation, ChREBP Molecular
715 Activation, Constitutive androstane receptor Activation, Constitutive androstane receptor Molecular
398 Activation, Dendritic Cells Activation, Dendritic Cells Cellular
941 Activation, EGFR Activation, EGFR Molecular
913 Activation, Epidermal Growth Factor Receptor Activation, Epidermal Growth Factor Receptor
1181 Activation, Estrogen receptor Activation, Estrogen receptor Molecular
1065 Activation, estrogen receptor alpha Activation, estrogen receptor alpha Molecular
116 Activation, FAS Activation, FAS Molecular
1197 Activation, Fibroblasts Activation, Fibroblasts Cellular
1293 Activation, FOXO Activation, FOXO Cellular
1304 Activation, FXR Activation, FXR Molecular
122 Activation, Glucocorticoid Receptor Activation, Glucocorticoid Receptor Molecular
760 Activation, Glutamate-gated chloride channel Activation, Glutamate-gated chloride channel Molecular
1018 Activation, Glutamate-gated chloride channels Activation, Glutamate-gated chloride channels Molecular
1157 Activation, Hepatic nuclear receptor(s) Activation, Hepatic nuclear receptor(s) Molecular
1280 Activation, HIF-1 Activation, HIF-1 Cellular
1303 Activation, HSD17B4 Activation, HSD17B4 Molecular
1010 Activation, iGABAR chloride channel Activation, iGABAR chloride channel
151 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways Molecular
1297 Activation, insulin receptor Activation, insulin receptor Molecular
762 Activation, ionotropic GABA Receptor chloride channel Activation, ionotropic GABA Receptor chloride channel Molecular
1282 Activation, JAK/STAT pathway Activation, JAK/STAT pathway Cellular
1292 Activation, JNK Activation, JNK Cellular
1205 Activation, Juvenile hormone receptor Activation, Juvenile hormone receptor Molecular
826 Activation, Keratinocytes Activation, Keratinocytes Cellular
1302 Activation, L-FABP Activation, L-FABP Molecular
165 Activation, Long term AHR receptor driven direct and indirect gene expression changes Activation, Long term AHR receptor driven direct and indirect gene expression changes Cellular
1314 Activation, LRH-1 Activation, LRH-1 Molecular
167 Activation, LXR Activation, LXR Molecular
483 Activation, LXR alpha Activation, LXR alpha Molecular
1198 Activation, Macrophages Activation, Macrophages Cellular
1300 Activation, mTORC1 Activation, mTORC1 Molecular
1298 Activation, mTORC2 Activation, mTORC2 Molecular
879 Activation, MTTP Activation, MTTP Cellular
1174 Activation, NADPH Oxidase Activation, NADPH Oxidase Molecular
559 Activation, Nicotinic acetylcholine receptor Activation, Nicotinic acetylcholine receptor Molecular
479 Activation, NR1H4 Activation, NR1H4 Molecular
478 Activation, NRF2 Activation, NRF2 Molecular
1310 Activation, PI3K Activation, PI3K Molecular
227 Activation, PPARα Activation, PPARα Molecular
234 Activation, PPARα & PPARγ Activation, PPARα & PPARγ Molecular
380 Activation, Pre-MIE: Metabolism of AFB1 Activation, Pre-MIE: Metabolism of AFB1 Molecular
239 Activation, Pregnane-X receptor, NR1l2 Activation, Pregnane-X receptor, NR1l2 Molecular
1369 Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Activation, PTGS-1 Molecular
1370 Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Activation, PTGS-2 Molecular
245 Activation, PXR/SXR Activation, PXR/SXR Molecular
258 Activation, SCD-1 Activation, SCD-1 Molecular
480 Activation, SHP Activation, SHP Molecular
924 Activation, Sp1 Activation, Sp1 Molecular
457 Activation, SREBF1 Activation, SREBF1 Molecular
1301 Activation, SREBP-1 Activation, SREBP-1 Molecular
264 Activation, SREBP-1c Activation, SREBP-1c Molecular
265 Activation, Stellate cells Activation, Stellate cells Cellular
978 Activation, Suppression of NFAT activation and hindrance of nuclear localization Activation, Suppression of NFAT activation and hindrance of nuclear localization Molecular
1283 Activation, TGF-beta pathway Activation, TGF-beta pathway Cellular
272 Activation/Proliferation, T-cells Activation/Proliferation, T-cells Organ
25 Agonism, Androgen receptor Agonism, Androgen receptor Molecular
111 Agonism, Estrogen receptor Agonism, Estrogen receptor Molecular
97 Alkylation, DNA Alkylation, DNA Molecular
244 Alkylation, Protein Alkylation, Protein Molecular
1210 Alteration, Food-web structures Alteration, Food-web structures Population
1060 Alteration, lipid metabolism Alteration, lipid metabolism Cellular
310 Alteration, Wnt pathway Alteration, Wnt pathway Cellular
854 Alterations, Cellular proliferation / hyperplasia Alterations, Cellular proliferation / hyperplasia Tissue
1214 Altered gene expression specific to CAR activation, Hepatocytes Altered expression of hepatic CAR-dependent genes Cellular
17 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways Molecular
21 Altered regulation, Alpha hemoglobin Altered regulation, Alpha hemoglobin Cellular
698 Altered, Action Potential Altered, Action Potential Cellular
1101 Altered, Amphibian metamorphosis Altered, Amphibian metamorphosis Organ
1243 Altered, Ca2+-calmodulin activated signal transduction Altered, Ca2+-calmodulin activated signal transduction Cellular
317 Altered, Cardiovascular development/function Altered, Cardiovascular development/function Organ
723 Altered, Chromosome number Altered, Chromosome number Cellular
536 Altered, Chromosome number (polyploid) zygote Altered, Chromosome number (polyploid) zygote Cellular
1211 Altered, food-web structures Altered, food-web structures Population
534 Altered, Formation of cortical envelope Altered, Formation of cortical envelope Cellular
1239 Altered, Gene Expression Altered, Gene Expression Molecular
339 Altered, Larval development Altered, Larval development Individual
752 Altered, Meiotic chromosome dynamics Altered, Meiotic chromosome dynamics Cellular
186 Altered, Neuroanatomy Altered, Neuroanatomy Organ
192 Altered, Neurophysiology Altered, Neurophysiology Organ
1240 Altered, Protein Production Altered, Protein Production Cellular
363 Altered, Reproductive behaviour Altered, Reproductive behaviour Individual
1428 Analgesia Analgesia Individual
1127 Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste
1073 anovulation, anovulation,
26 Antagonism, Androgen receptor Antagonism, Androgen receptor Molecular
112 Antagonism, Estrogen receptor Antagonism, Estrogen receptor Molecular
638 Antagonism, Histamine Receptor (H2) Antagonism, Histamine Receptor (H2) Molecular
1432 Anti-depressant Activity Anti-depressant Activity Individual
1169 Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment Molecular
1148 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of protein synthesis in bone Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p
1262 Apoptosis Apoptosis Cellular
525 Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Cellular
381 Reduced levels of BDNF BDNF, Reduced Molecular
214 Bile accumulation, Pathological condition Bile accumulation, Pathological condition Cellular
857 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain Molecular
667 Binding at picrotoxin site, iGABAR chloride channel Binding at picrotoxin site, iGABAR chloride channel Molecular
875 Binding of agonist, Ionotropic glutamate receptors Binding of agonist, Ionotropic glutamate receptors Molecular
387 Binding of agonist, NMDARs Binding of agonist, NMDARs Molecular
201 Binding of antagonist, NMDA receptors Binding of antagonist, NMDA receptors Molecular
998 Binding of antagonist, PPAR alpha Binding of antagonist, PPAR alpha Molecular
1199 Binding of FK506 to FKBP12, Binding of FK506 to FKBP12,
1200 Binding of FK506 to FKBP12, Formation Binding of FK506 to FKBP12, Formation
888 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Molecular
1486 Binding of substrate, endocytic receptor Binding of substrate, endocytic receptor Molecular
1485 Binding of substrate, endocytotic receptor Binding of substrate, endocytotic receptor Molecular
977 Binding, Binding of calcineurin with FK506-FKBP complexes Binding, Binding of calcineurin with FK506-FKBP complexes
1201 Binding, Immunophilins Binding, Immunophilins Molecular
261 Binding, SH-/selen-proteins Binding, SH-/selen-proteins Molecular
1487 Binding, Thiol/seleno-proteins involved in protection against oxidative stress Binding, SH/SeH proteins involved in protection against oxidative stress Molecular
957 Binding, Transthyretin in serum Binding, Transthyretin in serum Molecular
718 Binding, Tubulin Binding, Tubulin Molecular
301 Binding, VEGF-A Binding, VEGF-A
1529 Blockade, L-Type Calcium Channels Blockade, L-Type Calcium Channels Molecular
1132 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis Cellular
1149 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone proteins (periostin, MGP and periostin like factor) not formed Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1505 cell cycle, disrupted cell cycle, disrupted Cellular
1459 Induction, Cell damage sensing Cell damage sensing Molecular
429 Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alteration of cellular growth homeostasis Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alterati
853 Changes/Inhibition, Cellular Homeostasis and Apoptosis Changes/Inhibition, Cellular Homeostasis and Apoptosis Cellular
357 Cholestasis, Pathology Cholestasis, Pathology Individual
1454 chronic high fat diet chronic high fat diet Individual
1251 Chronic, Mucus hypersecretion Chronic, Mucus hypersecretion Tissue
491 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Organ
402 Cognitive Function, Decreased Cognitive Function, Decreased Individual
1275 Collagen Deposition Collagen Deposition Tissue
1221 Cough, Dyspnea, Sneezing, Acute respiratory effect Cough, Dyspnea, Sneezing, Acute respiratory effect
396 Covalent Binding, Protein Covalent Binding, Protein Molecular
1508 CYP2E1 Activation CYP2E1 Activation Molecular
1386 CYP7B activity, inhibition CYP7B activity, inhibition Molecular
1516 Increase, D1 protein blockage D1 protein blockage Molecular
829 Damage, Lipid bilayer Damage, Lipid bilayer Cellular
176 Damaging, Mitochondria Damaging, Mitochondria Cellular
250 Damaging, Red blood cells; hemolysis Damaging, Red blood cells; hemolysis Cellular
563 Death/Failure, Colony Death/Failure, Colony Population
361 Decline, Population Decline, Population Population
679 Decline, Population trajectory Decline, Population trajectory Population
686 Declining, Population trajectory Declining, Population trajectory Population
1258 Decompartmentalization Decompartmentalization Cellular
993 Decrease, Abdominal muscle contraction Decrease, Abdominal muscle contraction Tissue
973 KE5 : Decrease, AKT/eNOS activity Decrease, AKT/eNOS activity Cellular
914 Decrease, Apoptosis of ciliated epithelial cells Decrease, Apoptosis of ciliated epithelial cells Cellular
35 Decrease, Aromatase (Cyp19a1) Decrease, Aromatase (Cyp19a1) Cellular
792 Decrease, Bioactivation of testosterone Decrease, Bioactivation of testosterone Tissue
1534 Decrease, Blood pressure Decrease, Blood pressure Individual
1531 Decrease, Calcium binding to Troponin C Decrease, Calcium binding to Troponin C Cellular
1530 Decrease, Calcium currents Decrease, Calcium currents Cellular
1532 Decrease, Cardiac contractility Decrease, Cardiac contractility Organ
1533 Decrease, Cardiac ejection fraction Decrease, Cardiac ejection fraction Organ
1473 Decrease, Chlorophyll synthesis Decrease, Chlorophyll synthesis Cellular
1472 Decrease, Chloroplast ATP production Decrease, Chloroplast ATP production Cellular
1266 Decrease, Circulating crustacean cardioactive peptide Decrease, Circulating CCAP Tissue
988 Decrease, Circulating ecdysis triggering hormone Decrease, Circulating ETH Tissue
1523 Decrease, Cuticular chitin synthesis Decrease, Cuticular chitin synthesis Tissue
1313 Decrease, cytosolic fatty acid Decrease, cytosolic fatty acid Molecular
1056 Decrease, E2 blood concentrations at hypothalamus Decrease, E2 blood concentrations at hypothalamus Tissue
1267 Decrease, Ecdysis motoneuron bursts Decrease, Ecdysis motoneuron bursts Tissue
1268 Decrease, Excitatory postsynaptic potential Decrease, Excitatory postsynaptic potential Tissue
328 Decrease, Fecundity Decrease, Fecundity Individual
330 Decrease, Fertility Decrease, Fertility Individual
1476 Decrease, Glycolysis Decrease, Glycolysis Cellular
935 KE2 : Decrease, GTPCH-1 Decrease, GTPCH-1 Cellular
633 Decrease, histaminergic neuron excitation Decrease, histaminergic neuron excitation Cellular
788 Decrease, Incorporation of active iodide into iodotyrosines Decrease, Incorporation of active iodide into iodotyrosines Cellular
867 Decrease, Intracellular pH Decrease, Intracellular pH Cellular
1478 Decrease, Leaf cell mitosis Decrease, Leaf cell mitosis Tissue
1479 Decrease, Leaf development Decrease, Leaf development Organ
1377 Decrease, leukocyte adherence Decrease, leukocyte adherence Tissue
1474 Decrease, Light harvest capacity Decrease, Light harvest capacity Cellular
1250 Decrease, Lung function Decrease, Lung function Individual
40 Decrease, Mitochondrial ATP production Decrease, Mitochondrial ATP production Cellular
572 Decrease, Number of worker bees Decrease, Number of worker bees Population
1366 Decrease, Oogenesis Decrease, Oogenesis Cellular
488 Decrease, Ovulation Decrease, Ovulation Organ
1477 Decrease, Oxidative phosphorylation Decrease, OXPHOS Cellular
1475 Decrease, Photosynthesis Decrease, Photosynthesis Cellular
360 Decrease, Population trajectory Decrease, Population trajectory Population
771 Decrease, Serum thyroid hormone (T4/T3) Decrease, Serum thyroid hormone (T4/T3) Tissue
259 Decrease, Serum thyroxine (T4) Decrease, Serum thyroxine (T4)
266 Decrease, Steroidogenic acute regulatory protein (STAR) Decrease, Steroidogenic acute regulatory protein (STAR) Cellular
1382 Decrease, surfactant Decrease, surfactant Molecular
934 KE3 : Decrease, Tetrahydrobiopterin Decrease, Tetrahydrobiopterin Cellular
289 Decrease, Translocator protein (TSPO) Decrease, Translocator protein (TSPO) Cellular
642 Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Molecular
646 Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Organ
645 Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Cellular
644 Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membra Molecular
643 Decreased Cholesterol, Decreased Uptake of Lipoproteins Decreased Cholesterol, Decreased Uptake of Lipoproteins Molecular
1452 decreased DNA methylation of tyrosine hydroxylase decreased DNA methylation of tyrosine hydroxylase Cellular
1450 decreased dopamine decreased dopamine Molecular
543 Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult test Individual
972 Decreased fertility, Reduced number of oocytes ovulated Decreased fertility, Reduced number of oocytes ovulated Individual
969 Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Cellular
968 Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces Cellular
970 Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituit Cellular
1453 decreased methylation of dopamine transporter promoter decreased methylation of dopamine transporter promoter Cellular
656 Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
967 Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation de Organ
1451 decreased reward decreased reward Individual
505 Decreased sperm quantity / quality in the adult, Decreased fertility Decreased sperm quantity / quality in the adult, Decreased fertility Individual
520 Decreased sperm quantity or quality in the adult, Decreased fertility Decreased sperm quantity or quality in the adult, Decreased fertility Individual
649 Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Tissue
647 Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cell Cellular
648 Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Tissue
640 Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Molecular
660 decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
659 Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Cellular
654 Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid recept Cellular
661 Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Molecular
541 Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Cellular
657 Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Organ
540 Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Organ
662 Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Molecular
653 Decreased testosterone by the fetal Leydig cells, Increased corticosterone Decreased testosterone by the fetal Leydig cells, Increased corticosterone Cellular
655 Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Cellular
658 Decreased testosterone by the fetal Leydig cells, Increased estradiol Decreased testosterone by the fetal Leydig cells, Increased estradiol Cellular
8 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Cellular
1401 Decreased, 5-HT3 Decreased, 5-HT3 Tissue
742 Decreased, Androgen receptor activity Decreased, Androgen receptor activity Molecular
1409 Decreased, angiogenesis Decreased, angiogenesis Tissue
627 Decreased, anxiety Decreased, anxiety Individual
1183 Decreased, Apoptosis (Epithelial Cells) Decreased, Apoptosis (Epithelial Cells) Cellular
800 Decreased, Aromatase (Cyp19a1) mRNA Decreased, Aromatase (Cyp19a1) mRNA Cellular
1407 Decreased, bicarbonate Decreased, bicarbonate Tissue
1058 Decreased, bile flow Decreased, bile flow Organ
848 Decreased, Binding of NE to NE receptors on GnRH neurons Decreased, Binding of NE to NE receptors on GnRH neurons Cellular
315 Decreased, Body length Decreased, Body length
864 Decreased, Body Weight Decreased, Body Weight Individual
52 Decreased, Calcium influx Decreased, Calcium influx Cellular
1178 Decreased, Chloride conductance Decreased, Chloride conductance
807 Decreased, cholesterol Decreased, cholesterol Cellular
533 Decreased, Cortical granule release/distribution upon fertilization Decreased, Cortical granule release/distribution upon fertilization Cellular
527 Decreased, Decreased fecundity Decreased, Decreased fecundity Individual
482 Decreased, DHB4/HSD17B4 Decreased, DHB4/HSD17B4 Molecular
996 Decreased, Digestion of old cuticle Decreased, Digestion of old cuticle Organ
1083 Decreased, Dopaminergic activity Decreased, Dopaminergic activity Cellular
1319 Decreased, extracellular chloride (Cl-) Decreased, extracellular chloride (Cl-) Molecular
1318 Decreased, extracellular sodium (Na+) Decreased, extracellular Na+ Molecular
1347 Decreased, extracellular serotonin Decreased, extracellular serotonin Molecular
1414 Decreased, GABA Decreased, GABA Cellular
1179 Decreased, GABA release Decreased, GABA release Cellular
1145 Decreased, gametogenesis Decreased, gametogenesis
819 Decreased, Glomerular filtration Decreased, Glomerular filtration Tissue
578 Decreased, Glucose oxidase enzyme activity Decreased, Glucose oxidase enzyme activity Molecular
529 Decreased, GnRH cfos activity Decreased, GnRH cfos activity Molecular
530 Decreased, GnRH pulsatility/release Decreased, GnRH pulsatility/release Cellular
1071 Decreased, GnRH pulsatility/release in hypothalamus Decreased, GnRH pulsatility/release in hypothalamus Cellular
140 Decreased, HSD17B10 expression Decreased, HSD17B10 expression Cellular
579 Decreased, Hydrogen peroxide production Decreased, Hydrogen peroxide production Molecular
1416 Decreased, intracellular chloride Decreased, intracellular chloride Cellular
1323 Decreased, intracellular serotonin Decreased, intracellular serotonin Molecular
1177 Decreased, Ionotropic GABA receptor chloride channel conductance Decreased, Ionotropic GABA receptor chloride channel conductance Cellular
477 Decreased, Ketogenesis Decreased, Ketogenesis Cellular
861 Decreased, Ketogenesis (production of ketone bodies) Decreased, Ketogenesis (production of ketone bodies) Cellular
531 Decreased, LH Surge Decreased, LH Surge Cellular
1072 Decreased, LH Surge from anterior pituitary Decreased, LH Surge from anterior pituitary Cellular
635 Decreased, locomotion Decreased, locomotion Individual
166 Decreased, Long-term potentiation (LTP) Decreased, Long-term potentiation (LTP) Organ
168 Decreased, Lymphocytes Decreased, Lymphocytes Individual
805 Decreased, mevalonate Decreased, mevalonate Cellular
860 Decreased, Mitochondrial Fatty Acid Beta Oxidation Decreased, Mitochondrial Fatty Acid Beta Oxidation Molecular
179 Decreased, Mitochondrial fatty acid beta-oxidation Decreased, Mitochondrial fatty acid beta-oxidation Molecular
1404 Decreased, mucosal blood flow Decreased, mucosal blood flow Tissue
1406 Decreased, mucous Decreased, mucous Tissue
618 Decreased, Neuronal network function in adult brain Decreased, Neuronal network function in adult brain Organ
1330 Decreased, neuroplasticity Decreased, neuroplasticity Molecular
193 Decreased, Nitric Oxide Decreased, Nitric Oxide Cellular
1045 Decreased, Ovarian E2 Decreased, Ovarian E2 Tissue
1324 Decreased, packaged serotonin Decreased, packaged serotonin Molecular
216 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Cellular
859 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
765 Decreased, population 1 Decreased, population 1 Population
992 Decreased, Population 2 Decreased, Population 2
997 Decreased, Population size Decreased, Population size Population
442 Decreased, Population trajectory Decreased, Population trajectory Population
231 Decreased, PPAR-alpha activation Decreased, PPAR-alpha activation Molecular
232 Decreased, PPAR-beta activation Decreased, PPAR-beta activation Molecular
233 Decreased, PPAR-gamma activation Decreased, PPAR-gamma activation Molecular
858 Decreased, PPARalpha transactivation of gene expression Decreased, PPARalpha transactivation of gene expression Molecular
749 Decreased, Progesterone from corpus luteum Decreased, Progesterone from corpus luteum Tissue
747 Decreased, Prolactin Decreased, Prolactin Tissue
1104 Decreased, Prostaglandin F2alpha concentration, plasma Decreased, Prostaglandin F2alpha concentration, plasma Tissue
681 Decreased, Prostaglandin F2alpha synthesis, ovary Decreased, Prostaglandin F2alpha synthesis, ovary Organ
1055 Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamu
825 Decreased, Renal ability to dilute urine Decreased, Renal ability to dilute urine Organ
820 Decreased, Renal plasma flow Decreased, Renal plasma flow Tissue
1141 Decreased, Reproductive Success Decreased, Reproductive Success Individual
1327 Decreased, seizure Decreased, seizure Individual
1317 Decreased, serotonin transporter activity Decreased, serotonin transporter activity Molecular
1022 Decreased, serum T4/T3 Decreased, serum T4/T3 Tissue
629 Decreased, sheltering Decreased, sheltering Individual
585 Decreased, Sodium conductance 1 Decreased, Sodium conductance 1 Cellular
1176 Decreased, sodium conductance 2 Decreased, sodium conductance 2 Cellular
821 Decreased, Sodium reabsorption Decreased, Sodium reabsorption Organ
636 Decreased, survival Decreased, survival Population
1325 Decreased, synaptic release Decreased, synaptic release Molecular
989 Decreased, synthesis and secretion of molting fluid proteases Decreased, synthesis and secretion of molting fluid proteases
994 Decreased, Synthesis of molting fluid proteases Decreased, Synthesis of molting fluid proteases Tissue
528 Decreased, Synthesis of NE Decreased, Synthesis of NE Cellular
808 Decreased, Testosterone Decreased, Testosterone Individual
743 Decreased, Testosterone binding to androgen receptor (hypothalamus) Decreased, Testosterone binding to androgen receptor (hypothalamus) Molecular
426 Decreased, Thyroxine (T4) in serum Decreased, Thyroxine (T4) in serum Tissue
1093 Decreased, Thyroxine (T4) in tissues Decreased, Thyroxine (T4) in tissues Tissue
286 Decreased, Transcription of genes by AR Decreased, Transcription of genes by AR Cellular
1003 Decreased, Triiodothyronine (T3) in serum Decreased, Triiodothyronine (T3) in serum Tissue
1116 Decreased, Triiodothyronine (T3) in tissues Decreased, Triiodothyronine (T3) in tissues Tissue
737 Decreased, Uptake of inorganic iodide Decreased, Uptake of inorganic iodide Cellular
304 Decreased, VegfR2 Decreased, VegfR2
1295 Defect of Embryogenesis Defect of Embryogenesis Tissue
890 Degeneration of dopaminergic neurons of the nigrostriatal pathway Degeneration of dopaminergic neurons of the nigrostriatal pathway Organ
428 Delay, Developmental GABA shift Delay, Developmental GABA shift Cellular
532 Delayed, Ovulation Delayed, Ovulation Individual
1140 Delayed, Sexual maturity Delayed, Sexual maturity Individual
228 peroxisome proliferator activated receptor promoter demethylation demethylation, PPARg promoter Molecular
1143 Depletion, energy reserves Depletion, energy reserves Individual
130 Depletion, GSH Depletion, GSH Cellular
1482 Depletion, mtDNA Depletion, mtDNA Cellular
933 KE6 : Depletion, Nitric Oxide Depletion, Nitric Oxide Cellular
720 Depolymerization, Microtubule Depolymerization, Microtubule Molecular
663 Desensitization, Nicotinic acetylcholine receptor Desensitization, Nicotinic acetylcholine receptor Molecular
1456 Increase, Differentiation of fibroblasts Differentiation of fibroblasts Cellular
1272 Differentiation of Myofibroblast Differentiation of Myofibroblast Cellular
944 dimerization, AHR/ARNT dimerization, AHR/ARNT Molecular
652 Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig Cellular
1260 Direct mitochondrial inhibition Direct mitochondrial inhibition Molecular
721 Disorganization, Spindle Disorganization, Spindle Cellular
958 Displacement, Serum thyroxine (T4) from transthyretin Displacement, Serum thyroxine (T4) from transthyretin Molecular
1536 Disruption, Intracellular calcium mobilization Disruption, Intracellular calcium mobilization Cellular
898 Disruption, Lysosome Disruption, Lysosome Cellular
169 Disruption, Membrane integrity Disruption, Membrane integrity Cellular
178 Disruption, Mitochondrial electron transport chain Disruption, Mitochondrial electron transport chain Cellular
1537 Disruption, Sarcomere assembly Disruption, Sarcomere assembly Cellular
831 Disturbance, Lysosomal function Disturbance, Lysosomal function Cellular
1388 Dopamine release in the brain, decreased Dopamine release in the brain, decreased Tissue
472 Down Regulation, CPT1A Down Regulation, CPT1A Molecular
1286 Down Regulation, GSS and GSTs gene Down Regulation, GSS and GSTs gene Cellular
131 Down Regulation, Gulcose-6-phosphate dehydrogenase Down Regulation, Gulcose-6-phosphate dehydrogenase Cellular
474 Down Regulation, HMGCS2 Down Regulation, HMGCS2 Molecular
427 Down Regulation, K-Cl co-transporter 2 (KCC2) Down Regulation, K-Cl co-transporter 2 (KCC2) Cellular
1461 DNA double-strand break DSB Molecular
1483 Dysfunction, Mitochondria Dysfunction, Mitochondria Cellular
1184 Dysfunction, Mitochondrial Dynamics Dysfunction, Mitochondrial Dynamics
1248 EGFR , Activation EGFR , Activation
1247 EGFR , PPAR-alpha activation EGFR , PPAR-alpha activation
222 Elimination of (high doses), Posterior cardinal vein Elimination of (high doses), Posterior cardinal vein
1457 Induction, Epithelial Mesenchymal Transition EMT Cellular
1539 Endocytotic lysosomal uptake endocytosis Molecular
1180 Estrogen receptor activation, Estrogen receptor activation,
1220 Trigeminal nerve activation Excitation, Trigeminal nerve excitation Tissue
1273 Expression of Collagen Expression of Collagen Cellular
1131 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo Molecular
1119 Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII,
1130 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Organ
1528 Fatty Acid Beta Oxidation, Decreased Fatty Acid Beta Oxidation, Decreased Molecular
240 Feminisation or incomplete development, Primary and accessory male sex organs Feminisation or incomplete development, Primary and accessory male sex organs Organ
1442 Foam cell formation Foam cell formation Organ
118 Formation, Formation of hemoglobin adducts Formation, Formation of hemoglobin adducts Cellular
856 Formation, Hepatocellular and Bile duct tumors Formation, Hepatocellular and Bile duct tumors Organ
840 Formation, Liver fibrosis Formation, Liver fibrosis Tissue
347 Formation, Liver tumor Formation, Liver tumor Individual
839 Formation, Mallory body Formation, Mallory body Cellular
373 Formation, Pro-mutagenic DNA Adducts Formation, Pro-mutagenic DNA Adducts Molecular
976 Formation, The binding of FK506 with FKBP12 Formation, The binding of FK506 with FKBP12 Molecular
851 Decrease of GABAergic interneurons GABAergic interneurons, Decreased Cellular
1513 General Apoptosis General Apoptosis Cellular
1236 Generation of novel epitopes , Antigen presentation Generation of novel epitopes , Antigen presentation Cellular
682 Generation, Amplified excitatory postsynaptic potential (EPSP) Generation, Amplified excitatory postsynaptic potential (EPSP) Cellular
651 Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testostero Cellular
1488 Glutamate dyshomeostasis Glutamate dyshomeostasis Cellular
1290 Glutathione homeostasis Glutathione homeostasis Cellular
1287 Glutathione synthesis Glutathione synthesis Cellular
1519 Glycolysis Glycolysis Cellular
921 Occurrence, Hyperplasia of goblet cells Goblet cell hyperplasia Tissue
494 Glucocorticoid Receptor Agonist, Activation GR Agonist, Activation Molecular
1521 Decrease, Growth Growth Individual
1467 Growth, reduction Growth, reduction Individual
1440 Formation of HDL-SAA HDL-SAA formation Cellular
1535 Heart failure Heart failure Organ
1412 Helicobacter pylori infection Helicobacter pylori infection Tissue
1124 Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon diox
1121 Hemorrhage , organ dysfunction, hypovolemic shock Hemorrhage , organ dysfunction, hypovolemic shock
1123 Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue
1133 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Tissue
1393 Hepatocytotoxicity Hepatocytotoxicity Cellular
1291 Hepatotoxicity Hepatotoxicity Cellular
757 Hippocampal anatomy, Altered Hippocampal anatomy, Altered Tissue
756 Hippocampal gene expression, Altered Hippocampal gene expression, Altered Tissue
758 Hippocampal Physiology, Altered Hippocampal Physiology, Altered Tissue
1503 Histone acetylation, increase Histone acetylation, increase Cellular
1502 Histone deacetylase inhibition Histone deacetylase inhibition Molecular
142 Hyperplasia, Hyperplasia Hyperplasia, Hyperplasia Tissue
415 Hyperplasia, Leydig cell Hyperplasia, Leydig cell Cellular
1078 Hyperplasia, Mammary gland Hyperplasia, Mammary gland Tissue
1052 Hyperplasia, ovarian epithelium Hyperplasia, ovarian epithelium Tissue
1051 Hyperplasia, ovarian stromal cells Hyperplasia, ovarian stromal cells Cellular
763 hyperpolarisation, neuron hyperpolarisation, neuron Cellular
943 Hypersecretion, Mucus Hypersecretion, Mucus Organ
952 Hypertension Hypertension Individual
1043 Hypertrophy/hyperplasia, smooth muscle Hypertrophy/hyperplasia, smooth muscle Cellular
1095 hyperuricemia, hyperuricemia,
1254 Infant leukaemia IFL Individual
364 Impaired development of, Reproductive organs Impaired development of, Reproductive organs Individual
1125 Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and other waste products, Hemorrhage, organ dysfunction and hypovolemic shock Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and oth
1136 Impaired recruitment , Population trajectory Impaired recruitment , Population trajectory Population
577 impaired, Development impaired, Development Individual
406 impaired, Fertility impaired, Fertility Individual
568 impaired, Hive thermoregulation impaired, Hive thermoregulation Population
697 impaired, ion channels impaired, ion channels Cellular
566 impaired, Larval development impaired, Larval development Population
637 impaired, Learning and memory impaired, Learning and memory Individual
889 Impaired, Proteostasis Impaired, Proteostasis Cellular
583 impaired, Thoracic shivering impaired, Thoracic shivering Individual
937 KE7 : Impaired, Vasodilation Impaired, Vasodilation Organ
110 Impairment, Endothelial network Impairment, Endothelial network Cellular
341 Impairment, Learning and memory Impairment, Learning and memory Individual
984 Impairment, T-cell dependent antibody response Impairment, T-cell dependent antibody response Individual
1328 Inactivated, 5-HTR (serotonin receptors) Inactivated, 5-HTR Molecular
1270 Inactivation of PPARγ Inactivation of PPARγ Molecular
1356 Inactive, membrane depolarization Inactive, membrane depolarization Molecular
1172 Increase activation, Nuclear factor kappa B (NF-kB) Increase activation, Nuclear factor kappa B (NF-kB) Molecular
1470 inherited mutations in offspring increase in inherited mutations Individual
416 Increase proliferation, Leydig cell Increase proliferation, Leydig cell Cellular
736 Increase, Adenomas/carcinomas (bronchioloalveolar) Increase, Adenomas/carcinomas (bronchioloalveolar) Tissue
741 Increase, Adenomas/carcinomas (follicular cell) Increase, Adenomas/carcinomas (follicular cell) Tissue
719 Increase, Adenomas/carcinomas (hepatocellular) Increase, Adenomas/carcinomas (hepatocellular) Tissue
713 Increase, Adenomas/carcinomas (renal tubular) Increase, Adenomas/carcinomas (renal tubular) Tissue
797 Increase, Adenomas/carcinomas (urothelial) Increase, Adenomas/carcinomas (urothelial) Tissue
313 Increase, Allergic Respiratory Hypersensitivity Response Increase, Allergic Respiratory Hypersensitivity Response Organ
1384 Increase, ammonium (NH4+) Increase, ammonium (NH4+) Molecular
728 Increase, Aneuploid offspring Increase, Aneuploid offspring Individual
1376 Increase, angiogenesis Increase, angiogenesis Tissue
1365 Increase, Apoptosis Increase, Apoptosis Cellular
1372 Increase, bicarbonate Increase, bicarbonate Molecular
401 Increase, Biliary excretion TH glucuronide Increase, Biliary excretion TH glucuronide Organ
50 Increase, Ca++ (intracellular) Increase, Ca++ (intracellular) Cellular
885 Increase, Cancer Increase, Cancer Tissue
1527 Increase, Cell membrane depolarization Increase, Cell membrane depolarization Cellular
870 Increase, Cell Proliferation Increase, Cell Proliferation Cellular
1182 Increase, Cell Proliferation (Epithelial Cells) Increase, Cell Proliferation (Epithelial Cells) Cellular
1522 Increase, Chitin synthase inhibition Increase, CHS inhibition Molecular
621 Increase, cilia movement Increase, cilia movement Tissue
1171 Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Cellular
1334 Increase, cortisone Increase, cortisone Molecular
1269 Increase, COX-2 expression Increase, COX-2 expression Molecular
320 Increase, Curved body axis Increase, Curved body axis
1305 Increase, cytosolic fatty acid Increase, cytosolic fatty acid Cellular
768 Increase, Cytotoxicity Increase, Cytotoxicity Cellular
770 Increase, Cytotoxicity (club cells) Increase, Cytotoxicity (club cells) Cellular
776 Increase, Cytotoxicity (corneal cells) Increase, Cytotoxicity (corneal cells) Cellular
780 Increase, Cytotoxicity (epithelial cells) Increase, Cytotoxicity (epithelial cells) Cellular
786 Increase, Cytotoxicity (hepatocytes) Increase, Cytotoxicity (hepatocytes) Cellular
709 Increase, Cytotoxicity (renal tubular cell) Increase, Cytotoxicity (renal tubular cell) Cellular
783 Increase, Cytotoxicity (tubular epithelial cells) Increase, Cytotoxicity (tubular epithelial cells) Cellular
794 Increase, Cytotoxicity (urothelial cells) Increase, Cytotoxicity (urothelial cells) Cellular
1194 Increase, DNA damage Increase, DNA Damage Molecular
746 Increase, Dopaminergic activity Increase, Dopaminergic activity Cellular
1264 Increase, Nuclear receptor E75b gene expression Increase, E75b expression Molecular
947 Increase, Early Life Stage Mortality Increase, Early Life Stage Mortality Individual
103 Increase, Ecdysone receptor agonism Increase, EcR agonism Molecular
773 Increase, Endometrial adenocarcinomas Increase, Endometrial adenocarcinomas Tissue
573 Increase, Energetic demands and therefore metabolic stress Increase, Energetic demands and therefore metabolic stress Individual
1364 Increase, Excessive reactive oxygen species generation Increase, Excessive ROS generation Molecular
115 Increase, FA Influx Increase, FA Influx Cellular
1444 Increase, Follicular atresia Increase, Follicular atresia Tissue
1265 Increase, Fushi tarazu factor-1 gene expression Increase, Ftz-f1 expression Molecular
1361 Increase, GABA Increase, GABA Molecular
1175 Increase, Genes involved in fatty acid oxidation Increase, Genes involved in fatty acid oxidation Cellular
1480 Increase, Growth inhibition Increase, Growth inhibition Individual
336 Increase, Heritable mutations in offspring Increase, Heritable mutations in offspring Individual
740 Increase, Hyperplasia (follicular cells) Increase, Hyperplasia (follicular cells) Cellular
782 Increase, Hyperplasia (forestomach epithelial cells) Increase, Hyperplasia (forestomach epithelial cells) Cellular
772 Increase, Hyperplasia (glandular epithelial cells of endometrium) Increase, Hyperplasia (glandular epithelial cells of endometrium) Cellular
744 Increase, Hyperplasia (Leydig cells) Increase, Hyperplasia (Leydig cells) Cellular
767 Increase, Hyperplasia (renal tubular cells) Increase, Hyperplasia (renal tubular cells) Cellular
735 Increase, Hyperplasia (terminal bronchiolar cells) Increase, Hyperplasia (terminal bronchiolar cells) Cellular
784 Increase, Hyperplasia (tubular epithelial cells) Increase, Hyperplasia (tubular epithelial cells) Cellular
796 Increase, Hyperplasia (urothelial) Increase, Hyperplasia (urothelial) Cellular
1343 Increase, hypertension Increase, hypertension Individual
739 Increase, Hypertrophy and proliferation (follicular cell) Increase, Hypertrophy and proliferation (follicular cell) Cellular
990 Increase, Incomplete ecdysis Increase, Incomplete ecdysis Individual
986 Increase, Increased susceptibility to infection Increase, Increased susceptibility to infection Individual
149 Increase, Inflammation Increase, Inflammation Cellular
777 Increase, Inflammation (corneal cells) Increase, Inflammation (corneal cells) Cellular
1338 Increase, inositol triphosphate Increase, inositol triphosphate Molecular
1296 Increase, insulin Increase, insulin Molecular
1339 Increase, intracellular calcium Increase, intracellular calcium Cellular
1378 Increase, leukocyte adherence Increase, leukocyte adherence Tissue
745 Increase, Leydig cell tumors Increase, Leydig cell tumors Cellular
1445 Increase, Lipid peroxidation Increase, Lipid peroxidation Cellular
161 Increase, Liver and splenic hemosiderosis Increase, Liver and splenic hemosiderosis Organ
414 Increase, Luteinizing hormone (LH) Increase, Luteinizing hormone (LH) Cellular
1333 Increase, mental stress Increase, mental stress Individual
716 Increase, Mitogenic cell proliferation (hepatocytes) Increase, Mitogenic cell proliferation (hepatocytes) Cellular
350 Increase, Mortality Increase, Mortality Individual
962 Increase, Mucin production Increase, Mucin production Cellular
1374 Increase, mucosal blood flow Increase, mucosal blood flow Tissue
1373 Increase, mucous Increase, mucous Molecular
185 Increase, Mutations Increase, Mutations Molecular
876 Increase, Mutations in Critical Genes Increase, Mutations in Critical Genes Molecular
1341 Increase, myosin light chain phosphorylation Increase, myosin light chain phosphorylation Molecular
733 Increase, Necrosis (terminal bronchiolar cells) Increase, Necrosis (terminal bronchiolar cells) Cellular
1526 Increase, Opening of voltage-dependent calcium channel Increase, Opening of voltage-dependent calcium channel Cellular
769 Increase, Oxidative metabolism Increase, Oxidative metabolism Cellular
1279 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Cellular
779 Increase, Papillomas/carcinomas (squamous cells) Increase, Papillomas/carcinomas (squamous cells) Cellular
358 Increase, Pericardial edema Increase, Pericardial edema Organ
1173 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids Molecular
220 Increase, Plasma vitellogenin concentrations Increase, Plasma vitellogenin concentrations Organ
1375 Increase, platelet aggregation Increase, platelet aggregation Tissue
623 Increase, predation Increase, predation Population
1524 Increase, Premature molting Increase, Premature molting Individual
774 Increase, Preneoplastic foci (hepatocytes) Increase, Preneoplastic foci (hepatocytes) Cellular
923 Increase, Proliferation of goblet cells Increase, Proliferation of goblet cells Cellular
246 Increase, RBC congestion in liver Increase, RBC congestion in liver Organ
778 Increase, Regenerative cell proliferation (corneal cells) Increase, Regenerative cell proliferation (corneal cells) Cellular
781 Increase, Regenerative cell proliferation (forestomach epithelial cells) Increase, Regenerative cell proliferation (forestomach epithelial cells) Cellular
787 Increase, Regenerative cell proliferation (hepatocytes) Increase, Regenerative cell proliferation (hepatocytes) Cellular
734 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Cellular
710 Increase, Regenerative cell proliferation (tubular epithelial cells) Increase, Regenerative cell proliferation (tubular epithelial cells) Cellular
795 Increase, Regenerative cell proliferation (urothelial cells) Increase, Regenerative cell proliferation (urothelial cells) Cellular
252 Increase, Renal pathology due to VTG deposition Increase, Renal pathology due to VTG deposition Organ
869 Increase, Respiratory or Squamous Metaplasia Increase, Respiratory or Squamous Metaplasia Tissue
257 Increase, Reactive oxygen species production Increase, ROS production Molecular
1348 Increase, seizure Increase, seizure Individual
872 Increase, Site of Contact Nasal Tumors Increase, Site of Contact Nasal Tumors Organ
1315 Increase, Selective Serotonin Reuptake Inhibitors (SSRIs) Increase, SSRIs Molecular
1525 Increase, Sulfonylurea receptor binding Increase, SUR binding Molecular
1381 Increase, surfactant Increase, surfactant Molecular
753 Increase, Thyroid-stimulating hormone (TSH) Increase, Thyroid-stimulating hormone (TSH) Tissue
868 Increase, Tissue Degeneration, Necrosis & Atrophy Increase, Tissue Degeneration, Necrosis & Atrophy Tissue
1446 Increase, Uncoupling of oxidative phosphorylation Increase, Uncoupling of OXPHOS Cellular
1471 Increase, Uncoupling of photophosphorylation Increase, Uncoupling of photophosphorylation Cellular
793 Increase, Urinary bladder calculi Increase, Urinary bladder calculi Organ
951 KE8 : Increase, Vascular Resistance Increase, Vascular Resistance Organ
1342 Increase, vascular smooth muscle contraction Increase, vascular smooth muscle contraction Molecular
307 Increase, Vitellogenin synthesis in liver Increase, Vitellogenin synthesis in liver Tissue
1039 Increased activity, beta-2 adrenergic receptor Increased activity, beta-2 adrenergic receptor Molecular
1449 increased adipogenesis increased adipogenesis Tissue
1223 Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea Increased Airway Hyper-responsiveness,Cough, Dyspnea Tissue
1026 Increased Apoptosis, Adenomas/carcinomas (follicular cell) Increased Apoptosis, Adenomas/carcinomas (follicular cell) Tissue
496 Increased apoptosis, decreased number of adult Leydig Cells Increased apoptosis, decreased Leydig Cells Cellular
1500 Increased, fibroblast proliferation and myofibroblast differentiation Increased cellular proliferation and differentiation Tissue
1433 Increased CGRP, neuronal release of CGRP Increased CGRP Cellular
1501 Increased, extracellular matrix deposition Increased extracellular matrix deposition Tissue
1256 increased mantel display increased mantel display Organ
1435 Increased neurokinin A (NKA) by neuronal cells Increased NKA Cellular
1147 increased or inappropriate, mantel display increased or inappropriate, mantel display Individual
1493 Increased Pro-inflammatory mediators Increased pro-inflammatory mediators Tissue
1496 Increased, secretion of proinflammatory and profibrotic mediators Increased proinflammatory mediators Cellular
1030 Increased, Increased,
1326 Increased, 5-HT3 (5-hydroxytryptamine) Increased, 5-HT3 Molecular
708 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Tissue
134 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) Cellular
1082 Increased, adenomas (pituitary) Increased, adenomas (pituitary) Tissue
1079 Increased, Adenomas/carcinomas (mammary) Increased, Adenomas/carcinomas (mammary) Tissue
1070 Increased, adenosquamous carcinomas of endometrium Increased, adenosquamous carcinomas of endometrium Tissue
1029 Increased, adipogenesis Increased, adipogenesis Cellular
1345 Increased, agitation Increased, agitation Molecular
991 Increased, Alterations of food-web structures Increased, Alterations of food-web structures
591 Increased, amputations Increased, amputations Individual
1213 Increased, Angiogenesis Increased, Angiogenesis Cellular
880 Increased, ApoB100 Increased, ApoB100 Tissue
574 Increased, Appetite and hunger Increased, Appetite and hunger Individual
602 Increased, Ataxia, paralysis, or hyperactivity Increased, Ataxia, paralysis, or hyperactivity Organ
444 Increased, Atrioventricular block and bradycardia Increased, Atrioventricular block and bradycardia Organ
714 Increased, Binding of chemicals to 2u (serum) Increased, Binding of chemicals to 2u (serum) Molecular
1098 Increased, blood potassium concentration Increased, blood potassium concentration Tissue
1096 Increased, blood uric acid concentration Increased, blood uric acid concentration Tissue
699 Increased, cardiac arrthymia Increased, cardiac arrthymia Organ
863 Increased, Catabolism of Muscle Protein Increased, Catabolism of Muscle Protein Organ
1089 Increased, Cell Proliferation (mesothelium) Increased, Cell Proliferation (mesothelium) Cellular
1062 Increased, Cellular proliferation / hyperplasia of acinar cells Increased, Cellular proliferation / hyperplasia of acinar cells Cellular
761 Increased, Chloride conductance Increased, Chloride conductance Cellular
1011 Increased, Chloride influx Increased, Chloride influx
1059 Increased, cholestasis Increased, cholestasis Organ
696 Increased, Chromosome misseggregation Increased, Chromosome misseggregation Cellular
1162 Increased, cilia movement Increased, cilia movement Cellular
1076 Increased, circulating estrogen levels Increased, circulating estrogen levels Organ
961 Increased, Clearance of thyroxine from tissues Increased, Clearance of thyroxine from tissues Tissue
384 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
423 Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foci Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foc
693 Increased, cyclic adenosine monophosphate Increased, cyclic adenosine monophosphate Tissue
458 Increased, De Novo FA synthesis Increased, De Novo FA synthesis Cellular
1109 Increased, Deformed Wing Virus levels Increased, Deformed Wing Virus levels Individual
1346 Increased, depression Increased, depression Individual
1001 Increased, Developmental Defects Increased, Developmental Defects Molecular
323 Increased, Disease susceptibility Increased, Disease susceptibility Individual
1281 Increased, DNA Damage-Repair Increased, DNA Damage-Repair Cellular
1192 Increased, Ductal Hyperplasia Increased, Ductal Hyperplasia Tissue
1110 Increased, Energetic demands and therefore metabolic stress Increased, Energetic demands and therefore metabolic stress Individual
1363 Increased, epilepsy Increased, epilepsy Individual
1187 Increased, ER binding to DNA (classical pathway) Increased, ER binding to DNA (classical pathway) Molecular
1188 Increased, ER binding to T.F. to DNA (non-classical pathway) Increased, ER binding to T.F. to DNA (non-classical pathway) Molecular
748 Increased, Estrogen receptor (ER) activity Increased, Estrogen receptor (ER) activity Molecular
1320 Increased, extracellular serotonin Increased, extracellular serotonin Molecular
465 Increased, FA Influx Increased, FA Influx Cellular
460 Increased, Fatty acid uptake Increased, Fatty acid uptake Cellular
1035 Increased, Firbrosarcoma Increased, Firbrosarcoma Tissue
624 Increased, foot detachment Increased, foot detachment Individual
959 Increased, Free serum thyroxine (T4) Increased, Free serum thyroxine (T4) Tissue
421 Increased, glomerular rupture and renal hemorrhaging Increased, glomerular rupture and renal hemorrhaging Organ
1396 Increased, glucocorticoid receptor activity Increased, glucocorticoid receptor activity Molecular
1350 Increased, glutamate Increased, glutamate Molecular
1037 Increased, hemagiosarcoma Increased, hemagiosarcoma Tissue
1158 Increased, Hepatic thyroid hormone uptake/transport Increased, Hepatic thyroid hormone uptake/transport Tissue
802 Increased, HIF-1 alpha transcription Increased, HIF-1 alpha transcription Cellular
799 Increased, HIF-1 heterodimer Increased, HIF-1 heterodimer Cellular
1362 Increased, hippocampal hyperdepolarization Increased, hippocampal hyperdepolarization Molecular
1025 Increased, Hyperplasia (follicular cells) Increased, Hyperplasia (follicular cells) Tissue
1069 Increased, Hyperplasia (glandular epithelial cells of endometrium) Increased, Hyperplasia (glandular epithelial cells of endometrium) Cellular
1085 Increased, hyperplasia (mammary gland) Increased, hyperplasia (mammary gland) Tissue
1024 Increased, Hypertrophy and proliferation (follicular cell) Increased, Hypertrophy and proliferation (follicular cell) Cellular
1034 Increased, IGF-1 (mouse) Increased, IGF-1 (mouse) Cellular
376 Increased, Induced Mutations in Critical Genes Increased, Induced Mutations in Critical Genes Cellular
726 Increased, Induction of pyruvate dehydrogenase (PDH) Increased, Induction of pyruvate dehydrogenase (PDH) Molecular
1020 Increased, induction of UDPGT's in liver Increased, induction of UDPGT's in liver Cellular
1087 Increased, inflammation Increased, inflammation Cellular
1012 Increased, Inhibitory postsynaptic potential Increased, Inhibitory postsynaptic potential Cellular
493 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Molecular
389 Increased, Intracellular Calcium overload Increased, Intracellular Calcium overload Cellular
1322 Increased, intracellular chloride (Cl-) Increased, intracellular chloride (Cl-) Molecular
1398 Increased, intracellular serotonin Increased, intracellular serotonin Cellular
1321 Increased, intracellular sodium (Na+) Increased, intracellular sodium (Na+) Molecular
1196 Increased, Invasion Increased, Invasion Cellular
759 Increased, Kidney Failure Increased, Kidney Failure Individual
1081 Increased, lactotroph hyperplasia and hypertrophy Increased, lactotroph hyperplasia and hypertrophy Cellular
1080 Increased, latency period Increased, latency period Individual
467 Increased, LDL uptake Increased, LDL uptake Cellular
342 Increased, Lethality Increased, Lethality
1411 Increased, leukocyte activation Increased, leukocyte activation Tissue
1410 Increased, leukocyte adherence Increased, leukocyte adherence Tissue
791 Increased, Leutinizing hormone (LH) Increased, Leutinizing hormone (LH) Tissue
1306 Increased, lipogenesis Increased, lipogenesis Molecular
1036 Increased, liposarcoma Increased, liposarcoma Tissue
459 Increased, Liver Steatosis Increased, Liver Steatosis Organ
622 Increased, locomotion Increased, locomotion Individual
754 Increased, Luteinizing hormone (LH) Increased, Luteinizing hormone (LH) Tissue
1208 Increased, Male offspring Increased, Male offspring Population
1160 Increased, mantel display Increased, mantel display Individual
1090 Increased, mesotheliomas Increased, mesotheliomas Tissue
1190 Increased, Migration (Endothelial Cells) Increased, Migration (Endothelial Cells) Cellular
351 Increased, Mortality Increased, Mortality Population
1241 Increased, Motility Increased, Motility Cellular
625 Increased, muscular waves in foot Increased, muscular waves in foot Organ
422 Increased, nephropathy Increased, nephropathy Individual
1015 Increased, Neuronal synaptic inhibition Increased, Neuronal synaptic inhibition Cellular
1191 Increased, Non-genomic signaling Increased, Non-genomic signaling Cellular
1491 Increased, Oncotic Necrosis increased, oncotic necrosis Tissue
1161 Increased, oocyte maturation Increased, oocyte maturation Organ
356 Increased, Oxidative damage Increased, Oxidative damage Individual
1088 Increased, Oxidative Stress Increased, Oxidative Stress Cellular
1399 Increased, packaged serotonin Increased, packaged serotonin Cellular
1063 Increased, Pancreatic acinar tumors Increased, Pancreatic acinar tumors Organ
775 Increased, Plasma tyrosine Increased, Plasma tyrosine Tissue
1164 Increased, Population Increased, Population Population
1057 Increased, PPAR-alpha activation Increased, PPAR-alpha activation Molecular
588 Increased, predation Increased, predation Population
1077 Increased, prolactin exposure Increased, prolactin exposure Tissue
1084 Increased, prolactin secretion Increased, prolactin secretion Tissue
1189 Increased, Proliferation (Endothelial cells) Increased, Proliferation (Endothelial cells) Cellular
1033 Increased, proliferation of mesenchymal cells Increased, proliferation of mesenchymal cells Cellular
377 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered Hepatic Foci (AHF)) Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
1357 Increased, RDX dose Increased, RDX dose Molecular
1115 Increased, Reactive oxygen species Increased, Reactive oxygen species Cellular
1031 Increased, release of growth factors Increased, release of growth factors
419 Increased, renal vitellogenin deposition Increased, renal vitellogenin deposition Organ
1163 Increased, Reproductive Success Increased, Reproductive Success Individual
445 Increased, Respiratory distress/arrest Increased, Respiratory distress/arrest Organ
1159 Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin transporter Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin tr
1242 Increased, Second Messenger Production Increased, Second Messenger Production Cellular
1049 Increased, secrection of FSH from anterior pituitary Increased, secrection of FSH from anterior pituitary Cellular
1047 Increased, secretion of GnRH from hypothalamus Increased, secretion of GnRH from hypothalamus Cellular
1048 Increased, secretion of leutenizing hormone Increased, secretion of leutenizing hormone
1050 Increased, secretion of LH from anterior pituitary Increased, secretion of LH from anterior pituitary Cellular
1032 Increased, secretion of local growth factors Increased, secretion of local growth factors Cellular
1344 Increased, seizure Increased, seizure Individual
626 Increased, serotonin (5-HT) Increased, serotonin (5-HT) Cellular
620 Increased, serotonin (5-HT) 1 1 Increased, serotonin (5-HT) 1 Molecular
1397 Increased, serotonin transporter activity Increased, serotonin transporter activity Cellular
813 Increased, Serum creatinine Increased, Serum creatinine Organ
1418 Increased, steatosis Increased, steatosis Organ
366 Increased, Structural malformations Increased, Structural malformations
1400 Increased, synaptic release Increased, synaptic release Cellular
1021 Increased, T4/T3 catabolism Increased, T4/T3 catabolism Cellular
1023 Increased, Thyroid-stimulating hormone (TSH) Increased, Thyroid-stimulating hormone (TSH) Tissue
881 Increased, Triglyceride Increased, Triglyceride Cellular
454 Increased, Triglyceride formation Increased, Triglyceride formation Cellular
1154 Increased, Triiodothyronine (T3) in tissues Increased, Triiodothyronine (T3) in tissues Tissue
960 Increased, Uptake of thyroxine into tissue Increased, Uptake of thyroxine into tissue Cellular
1142 Increased, valve movement Increased, valve movement Tissue
576 Increased, Viral susceptibility Increased, Viral susceptibility Individual
418 Increased, Vitellogenin synthesis Increased, Vitellogenin synthesis Cellular
1166 Increased, water pumping Increased, water pumping Tissue
1139 Increased, water retention in foot Increased, water retention in foot Organ
1257 Induced parturition Induced parturition Individual
1255 induced spawning induced spawning Individual
1167 induced, parturition induced, parturition Individual
39 Induction, Ataxia, paralysis, or hyperactivity Induction, Ataxia, paralysis, or hyperactivity Organ
60 Induction, Chitin degradation and resorption Induction, Chitin degradation and resorption
850 Induction, CYP1A2/CYP1A5 Induction, CYP1A2/CYP1A5 Molecular
1206 Induction, Doublesex1 gene Induction, Doublesex1 gene Molecular
1312 Induction, fatty acid beta-oxidation Induction, fatty acid beta-oxidation Molecular
145 Induction, IKB inhibitory protein Induction, IKB inhibitory protein Cellular
164 Induction, Liver “Dysfunctional” Changes by CGA 330050 Induction, Liver “Dysfunctional” Changes by CGA 330050 Organ
1209 Induction, Male reproductive tract Induction, Male reproductive tract Organ
1207 Induction, Male traits formation in embryos Induction, Male traits formation in embryos
838 Induction, Microvesicular fat Induction, Microvesicular fat Tissue
1019 Induction, pharyngeal muscle paralysis Induction, pharyngeal muscle paralysis Tissue
238 Induction, Pre-mature molting Induction, Pre-mature molting
1014 Induction, Somatic muscle paralysis Induction, Somatic muscle paralysis Tissue
269 Induction, Sustained Cell Proliferation Induction, Sustained Cell Proliferation Cellular
270 Induction, Sustained Hepatotoxicity Induction, Sustained Hepatotoxicity Individual
295 Induction, Upregulation of glucuronyltransferase activity Induction, Upregulation of glucuronyltransferase activity Molecular
901 Infiltration, Inflammatory cells Infiltration, Inflammatory cells Tissue
907 Infiltration, Inflammatory cytokines Infiltration, Inflammatory cytokines
486 systemic inflammation leading to hepatic steatosis inflammation Organ
902 Inflammation, Liver Inflammation, Liver Organ
1216 Influx of Ca2+, Excitation of trigeminal nerves Influx of Ca2+, Excitation of trigeminal nerves
1331 Inhibit, agitation Inhibit, agitation Individual
1332 Inhibit, depression Inhibit, depression Individual
1367 Inhibit, gastric ulcer formation Inhibit, gastric ulcer formation Organ
1316 Inhibit, serotonin transporter activity Inhibit, serotonin transporter activity Molecular
1353 Inhibit, voltage-gated sodium channel Inhibit, voltage-gated sodium channel Molecular
59 Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis
964 Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle b Molecular
1429 Inhibition of N-type Ca ion channels Inhibition of Ca Channels Cellular
1490 Inhibition, Fatty Acid Beta Oxidation Inhibition of fatty acid beta oxidation Molecular
1463 Inhibition of lysyl oxidase Inhibition of lysyl oxidase Cellular
1430 Inhibition of neurotransmitter vesicle release Inhibition of neurotransmitter release Cellular
766 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Molecular
619 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Molecular
790 Inhibition, 5α-reductase activity Inhibition, 5α-reductase activity Cellular
12 Inhibition, Acetylcholinesterase (AchE) Inhibition, Acetylcholinesterase (AchE) Cellular
849 Inhibition, Antgonism of NE receptor Inhibition, Antgonism of NE receptor Molecular
36 Inhibition, Aromatase Inhibition, Aromatase Molecular
41 Inhibition, Bile Salt Export Pump (ABCB11) Inhibition, Bile Salt Export Pump (ABCB11) Molecular
51 Inhibition, Ca++ ATPase Inhibition, Ca++ ATPase Molecular
980 Inhibition, Calcineurin Activity Inhibition, Calcineurin Activity Molecular
1103 Inhibition, Cyclooxygenase 1 activity Inhibition, Cyclooxygenase 1 activity Molecular
79 Inhibition, Cyclooxygenase activity Inhibition, Cyclooxygenase activity Molecular
1009 Inhibition, Deiodinase 1 Inhibition, Deiodinase 1 Molecular
1002 Inhibition, Deiodinase 2 Inhibition, Deiodinase 2 Molecular
1153 Inhibition, Deiodinase 3 Inhibition, Deiodinase 3 Molecular
1156 Inhibition, Dual oxidase Inhibition, Dual oxidase Molecular
105 Inhibition, ECT complexes of the respiratory chain Inhibition, ECT complexes of the respiratory chain
593 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Molecular
1016 Inhibition, Feeding Inhibition, Feeding Individual
471 Inhibition, FoxA2 Inhibition, FoxA2 Molecular
804 Inhibition, HMG-CoA reductase Inhibition, HMG-CoA reductase Cellular
147 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Cellular
526 Inhibition, Inhibition of Dopamine-beta-hydroxylase Inhibition, Inhibition of Dopamine-beta-hydroxylase Molecular
1152 Inhibition, Iodotyrosine deiodinase (IYD) Inhibition, Iodotyrosine deiodinase (IYD) Molecular
1308 Inhibition, LRH-1 Inhibition, LRH-1 Molecular
1307 Inhibition, LXR Inhibition, LXR Molecular
1481 Inhibition of mitochondrial DNA polymerase gamma (Pol gamma) Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) Molecular
451 Inhibition, Mitochondrial fatty acid beta-oxidation Inhibition, Mitochondrial fatty acid beta-oxidation Molecular
1013 Inhibition, Motor neuron activity Inhibition, Motor neuron activity
424 Inhibition, Na+/I- symporter (NIS) Inhibition, Na+/I- symporter (NIS) Molecular
887 Inhibition, NADH-ubiquinone oxidoreductase (complex I) Inhibition, NADH-ubiquinone oxidoreductase (complex I) Cellular
195 Inhibition, NMDARs Inhibition, NMDARs Molecular
202 Inhibition, Nuclear factor kappa B (NF-kB) Inhibition, Nuclear factor kappa B (NF-kB) Molecular
877 Inhibition, organic anion transporter 1 (OAT1) Inhibition, organic anion transporter 1 (OAT1) Molecular
1155 Inhibition, Pendrin Inhibition, Pendrin Molecular
828 Inhibition, Phospholipase A Inhibition, Phospholipase A Molecular
468 Inhibition, PPAR alpha Inhibition, PPAR alpha Molecular
798 Inhibition, Prolyl hydroxylases Inhibition, Prolyl hydroxylases Cellular
1368 Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Inhibition, PTGS-1 Molecular
1371 Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Molecular
724 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Cellular
584 Inhibition, sodium channel Inhibition, sodium channel Molecular
878 Inhibition, SREBP1c Inhibition, SREBP1c Molecular
1311 Inhibition, Steatosis Inhibition, Steatosis Organ
845 Inhibition, UROD Inhibition, UROD Molecular
305 Inhibition, VegfR2 Inhibition, VegfR2 Molecular
1294 Inhibition, Wnt pathway Inhibition, Wnt pathway Cellular
832 Injury, Mitochondria Injury, Mitochondria Cellular
298 Insufficiency, Vascular Insufficiency, Vascular Molecular
1495 Increased, interaction with the resident cell membrane components Interaction with the cell membrane Molecular
979 Interference, nuclear localization of NFAT Interference, nuclear localization of NFAT Molecular
1074 interruption, Ovulation interruption, Ovulation Individual
405 irregularities, ovarian cycle irregularities, ovarian cycle Individual
1134 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle Molecular
1117 Irreversible inhibition of VKOR by binding at tyrosine 139, Irreversible inhibition of VKOR by binding at tyrosine 139,
1118 Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin
1434 Irritation of nasal mucosa inducing sneeze reflex Irritation induced sneezing Tissue
1225 Immune system inflammation Leukocyte infiltration Tissue
1494 Leukocyte recruitment/activation Leukocyte recruitment/activation Cellular
1511 Lipid Peroxidation Lipid Peroxidation Molecular
1395 Liver Cancer Liver Cancer Organ
1389 Locomotor activity, decreased Locomotor activity, decreased Individual
1498 Increased, loss of alveolar capillary membrane integrity Loss of alveolar capillary membrane integrity Tissue
319 Loss, Cochlear function Loss, Cochlear function Organ
1276 Lung fibrosis Lung fibrosis Organ
1246 Lung function, Decrease Lung function, Decrease
1540 lysosomal disruption lysosom Molecular
348 Malformation, Male reproductive tract Malformation, Male reproductive tract Organ
809 malformed, Male reproductive tract malformed, Male reproductive tract Individual
409 Metabolism of AFB1, Production of Reactive Electrophiles Metabolism of AFB1, Production of Reactive Electrophiles Molecular
1185 Mitochondrial Dysfunction, N/A Mitochondrial Dysfunction, N/A
1261 Mitochondrial impairment Mitochondrial impairment Molecular
1253 MLL chromosomal translocation MLL translocation Cellular
1195 modulation, Extracellular Matrix Composition modulation, Extracellular Matrix Composition Cellular
1170 modulation, Genes/proteins that regulate hepatocyte fate modulation, Genes/proteins that regulate hepatocyte fate Cellular
598 modulation, sodium channel modulation, sodium channel Molecular
801 modulation, Unknown modulation, Unknown Molecular
1425 Mu Opioid Receptor Agonism Mu Opioid Receptor Agonism Molecular
1245 Mucus , Hypersecretion Mucus , Hypersecretion
1244 Mucus hypersecretion, Mucus hypersecretion,
312 N/A, Allergic contact dermatitis on challenge N/A, Allergic contact dermatitis on challenge Individual
27 N/A, Androgen receptor, Antagonism N/A, Androgen receptor, Antagonism Molecular
764 N/A, Ataxia, paralysis, or hyperactivity N/A, Ataxia, paralysis, or hyperactivity Organ
1193 N/A, Breast Cancer N/A, Breast Cancer Individual
55 N/A, Cell injury/death N/A, Cell injury/death Cellular
75 N/A, Covalent binding to protein, possibly lysine residue N/A, Covalent binding to protein, possibly lysine residue Molecular
321 N/A, Cyanosis occurs N/A, Cyanosis occurs Individual
119 N/A, Gap N/A, Gap Tissue
139 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects Tissue
590 N/A, hypoxia N/A, hypoxia Tissue
337 N/A, Impairment of reproductive capacity N/A, Impairment of reproductive capacity Individual
155 N/A, Insufficient or incorrect DNA repair N/A, Insufficient or incorrect DNA repair Cellular
158 N/A, Interferences with SH-/selen-proteins N/A, Interferences with SH-/selen-proteins Cellular
344 N/A, Liver fibrosis N/A, Liver fibrosis Organ
345 N/A, Liver Steatosis N/A, Liver Steatosis Organ
173 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number Organ
177 N/A, Mitochondrial dysfunction 1 N/A, Mitochondrial dysfunction 1 Cellular
1186 N/A, Mitochondrial Dysfunction 2 N/A, Mitochondrial Dysfunction 2
352 N/A, Neurodegeneration N/A, Neurodegeneration Tissue
188 N/A, Neuroinflammation N/A, Neuroinflammation Tissue
191 N/A, Neuronal dysfunction N/A, Neuronal dysfunction Cellular
210 N/A, Oxidative stress N/A, Oxidative stress Cellular
213 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin Molecular
253 N/A, Reproductive failure N/A, Reproductive failure Individual
634 N/A, sedation N/A, sedation Individual
294 N/A, Unknown N/A, Unknown Molecular
1259 narcosis narcosis Cellular
1263 Necrosis Necrosis Tissue
1514 Neurodegeneration Neurodegeneration Organ
1436 neurogenic inflammation of sensory nerves neurogenic inflammation Cellular
386 Decrease of neuronal network function Neuronal network function, Decreased Organ
1417 NFE2/Nrf2 repression NFE2/Nrf2 repression Molecular
1235 Non-neuronal production of IL-8/CXCL1, Epithelial irritation Non-neuronal production of IL-8/CXCL1, Epithelial irritation Tissue
1224 Non-neuronal production of TNF, Epithelial irritation Non-neuronal production of TNF, Epithelial irritation Individual
862 Not Increased, Circulating Ketone Bodies Not Increased, Circulating Ketone Bodies Tissue
1466 Notochord distortion or malformations Notochord malformation Organ
1447 obesity obesity Individual
616 Occurrence, A paroxysmal depolarizing shift Occurrence, A paroxysmal depolarizing shift Tissue
835 Occurrence, Ballooning degeneration (hepatocyte) Occurrence, Ballooning degeneration (hepatocyte) Cellular
1106 Occurrence, cardiac arrhythmia Occurrence, cardiac arrhythmia Organ
1100 Occurrence, cardiac arrthymia Occurrence, cardiac arrthymia
823 Occurrence, Cystic dilatation (renal tubule) Occurrence, Cystic dilatation (renal tubule) Organ
836 Occurrence, Cytoplasmic vacuolization (Bile duct cell) Occurrence, Cytoplasmic vacuolization (Bile duct cell) Cellular
833 Occurrence, Cytoplasmic vacuolization (hepatocyte) Occurrence, Cytoplasmic vacuolization (hepatocyte) Cellular
837 Occurrence, Cytoplasmic vacuolization (kupffer cell) Occurrence, Cytoplasmic vacuolization (kupffer cell) Cellular
824 Occurrence, Cytoplasmic vacuolization (podocyte) Occurrence, Cytoplasmic vacuolization (podocyte) Organ
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) Occurrence, Cytoplasmic vacuolization (Renal tubule) Organ
613 Occurrence, Epileptic seizure Occurrence, Epileptic seizure Individual
814 Occurrence, Kidney toxicity Occurrence, Kidney toxicity Organ
920 Occurrence, Metaplasia of goblet cells Occurrence, Metaplasia of goblet cells Tissue
1112 Occurrence, Oxidative Stress Occurrence, Oxidative Stress
1105 Occurrence, renal ischemia Occurrence, renal ischemia Tissue
1097 Occurrence, renal proximal tubular necrosis Occurrence, renal proximal tubular necrosis Tissue
1102 Occurrence, tophi (urate) deposition Occurrence, tophi (urate) deposition Tissue
919 Occurrence, Transdifferentiation of ciliated epithelial cells Occurrence, Transdifferentiation of ciliated epithelial cells Cellular
1218 Opening of calcium channel, Calcium influx Opening of calcium channel, Calcium influx Cellular
1427 Opening of G protein gated inward rectifying K channels Opening of GIRK channels Cellular
1151 Osteoporosis and vascular calcification, Bone deterioration Osteoporosis and vascular calcification, Bone deterioration Individual
601 Overactivation, muscle contraction Overactivation, muscle contraction Tissue
600 Overactivation, Neuronotransmitter release Overactivation, Neuronotransmitter release Molecular
388 Overactivation, NMDARs Overactivation, NMDARs Molecular
664 Overwhelmed, Mitochondrial DNA repair mechanisms Overwhelmed, Mitochondrial DNA repair mechanisms Cellular
971 Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required f Individual
1238 Activation of oxidative stress pathway Oxidation Molecular
926 Oxidation, Glutathione (To be considered with MIE) Oxidation, Glutathione Molecular
844 Oxidation, Uroporphyrinogen Oxidation, Uroporphyrinogen Cellular
1392 Oxidative Stress Oxidative Stress Molecular
1510 Oxidative Stress in Brain Oxidative Stress in Brain Molecular
1249 Oxidative Stress, Oxidative Stress,
1231 Oxidization of biomolecules, Lipid bilayer and cellular proteins Oxidization of biomolecules, Lipid bilayer and cellular proteins
1520 Oxidative phosphorylation OXPHOS Cellular
1504 p21 (CDKN1A) expression, increase p21 (CDKN1A) expression, increase Cellular
896 Parkinsonian motor deficits Parkinsonian motor deficits Individual
209 Peptide Oxidation Peptide Oxidation Molecular
1086 persistent, cytotoxicity (pleura or peritoneum) persistent, cytotoxicity (pleura or peritoneum) Cellular
1289 Perturbation of cholesterol Perturbation of cholesterol Cellular
1518 Photosynthesis, Decrease Photosynthesis Cellular
1091 Physical and/or chemical interaction with cellular components, Physical and/or chemical interaction with cellular components,
1443 Plaque progression in arteries Plaque progression Individual
1146 premature, Spawning premature, Spawning Individual
1144 premature, spawning 1 1 premature, spawning 1
1064 prepubertal increase, Estrogen receptor (ER) activity prepubertal increase, Estrogen receptor (ER) activity Molecular
1438 Increased production of pulmonary, pro-inflammatory cytokines Pro-inflammatory cytokines increased Molecular
1232 Production of nerve growth factor , Production of nerve growth factor ,
1234 Production of nerve growth factor , Epithelial irritation Production of nerve growth factor , Epithelial irritation Tissue
1274 Production of α-smooth muscle actin Production of α-smooth muscle actin Cellular
77 Production, Critical Metabolites (CGA 330050 and CGA 265307) Production, Critical Metabolites (CGA 330050 and CGA 265307) Cellular
1233 Production, Nerve growth factor Production, Nerve growth factor
249 Production, Reactive oxygen species Production, Reactive oxygen species Tissue
302 Production, VEGF-A Production, VEGF-A
57 Proliferation, Cell proliferation in the absence of cytotoxicity Proliferation, Cell proliferation in the absence of cytotoxicity Cellular
1041 Proliferation, smooth muscle Proliferation, smooth muscle
1067 Proliferation/Clonal Expansion, aberrant basal cells Proliferation/Clonal Expansion, aberrant basal cells Cellular
1042 Proliferation/Clonal Expansion, smooth muscle Proliferation/Clonal Expansion, smooth muscle Cellular
599 prolonged, Depolarization of neuronal membrane prolonged, Depolarization of neuronal membrane Cellular
1061 prolonged, elevation of serun CCK prolonged, elevation of serun CCK Tissue
1075 prolonged, estrus prolonged, estrus Individual
334 Promotion, Hepatocelluar carcinoma Promotion, Hepatocelluar carcinoma Individual
1044 Promotion, mesovarian leiomyomas Promotion, mesovarian leiomyomas Tissue
1053 Promotion, ovarian adenomas Promotion, ovarian adenomas Tissue
1054 Promotion, ovarian granular cell tumors Promotion, ovarian granular cell tumors Cellular
1066 Promotion, SIX-1 postive basal-type progenitor cells Promotion, SIX-1 postive basal-type progenitor cells Cellular
211 Propagation, Oxidative stress Propagation, Oxidative stress Molecular
1538 Decreased protection against oxidative stress Protection against oxidative stress, decreased Cellular
1509 Protein Adduct Formation Protein Adduct Formation Molecular
1517 Decrease, Photosystem II activity PSII activity Molecular
1458 Pulmonary fibrosis Pulmonary fibrosis Organ
1092 Pulmonary Fibrosis, Pulmonary Fibrosis,
1484 Receptor mediated endocytosis Receptor mediated endocytosis Molecular
1497 Increased, recruitment of inflammatory cells Recruitment of inflammatory cells Cellular
1329 Reduce expression, BDNF (Brain-derived neurotrophic factor) Reduce expression, BDNF Molecular
945 reduced dimerization, ARNT/HIF1-alpha reduced dimerization, ARNT/HIF1-alpha Molecular
966 Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulos Tissue
1135 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Tissue
948 reduced production, VEGF reduced production, VEGF Cellular
674 Reduced, Ability to attract spawning mates Reduced, Ability to attract spawning mates Individual
1007 Reduced, Anterior swim bladder inflation Reduced, Anterior swim bladder inflation Tissue
580 Reduced, Antiseptic incorporated in food Reduced, Antiseptic incorporated in food Population
1335 Reduced, BDNF (Brain-derived neurotrophic factor) Reduced, BDNF Molecular
565 Reduced, Brood care Reduced, Brood care Population
1424 Reduced, fatty acid beta oxidation Reduced, fatty acid beta oxidation Molecular
587 Reduced, feeding 1 Reduced, feeding 1 Individual
1017 Reduced, Feeding 2 Reduced, Feeding 2
561 Reduced, Food storage Reduced, Food storage Population
1419 Reduced, FXR activity Reduced, FXR activity Molecular
1415 Reduced, GABA-A receptor activation Reduced, GABA-A receptor activation Molecular
689 Reduced, Gonadotropin releasing hormone, hypothalamus Reduced, Gonadotropin releasing hormone, hypothalamus Tissue
1008 Reduced, Hearing Reduced, Hearing Organ
1423 Reduced, HSD17B4 activity Reduced, HSD17B4 activity Molecular
690 Reduced, Luteinizing hormone (LH), plasma Reduced, Luteinizing hormone (LH), plasma Tissue
692 Reduced, Maturation inducing steroid receptor signalling, oocyte Reduced, Maturation inducing steroid receptor signalling, oocyte Tissue
691 Reduced, Maturation inducing steroid, plasma Reduced, Maturation inducing steroid, plasma Tissue
694 Reduced, Meiotic prophase I/metaphase I transition, oocyte Reduced, Meiotic prophase I/metaphase I transition, oocyte Cellular
1405 Reduced, mucosal defense Reduced, mucosal defense Tissue
1212 Reduced, Neuronal synaptic inhibition Reduced, Neuronal synaptic inhibition Cellular
678 Reduced, Pheromone release Reduced, Pheromone release Individual
1403 Reduced, platelet aggregation Reduced, platelet aggregation Tissue
1004 Reduced, Posterior swim bladder inflation Reduced, Posterior swim bladder inflation Organ
1422 Reduced, PPARalpha Reduced, PPARalpha Molecular
1413 Reduced, presynaptic neuron 2 activity Reduced, presynaptic neuron 2 activity Cellular
383 Reduced, Presynaptic release of glutamate Reduced, Presynaptic release of glutamate Molecular
687 Reduced, Prostaglandin E2 concentration, hypothalamus Reduced, Prostaglandin E2 concentration, hypothalamus Tissue
671 Reduced, Prostaglandin F2alpha concentration, plasma Reduced, Prostaglandin F2alpha concentration, plasma Individual
672 Reduced, Prostaglandin F2alpha synthesis, ovary Reduced, Prostaglandin F2alpha synthesis, ovary Organ
685 Reduced, Prostaglandins, ovary Reduced, Prostaglandins, ovary Organ
1402 Reduced, PTGS1 function Reduced, PTGS1 function Molecular
1408 Reduced, PTGS2 function Reduced, PTGS2 function Cellular
675 Reduced, Reproductive Success Reduced, Reproductive Success Individual
1420 Reduced, SHP activity Reduced, SHP activity Molecular
673 Reduced, Spawning behavior Reduced, Spawning behavior Individual
592 Reduced, survival Reduced, survival Population
1005 Reduced, Swimming performance Reduced, Swimming performance Individual
586 Reduced, swimming speed Reduced, swimming speed Individual
1006 Reduced, Young of year survival Reduced, Young of year survival Individual
965 reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic producti Cellular
408 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) reduction in ovarian granulosa cells, Aromatase (Cyp19a1) Cellular
29 Reduction in, Angiogenic sprouts Reduction in, Angiogenic sprouts
1464 Reduction of collagen crosslinking Reduction of collagen crosslinking Tissue
3 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Cellular
28 Reduction, Angiogenesis Reduction, Angiogenesis Molecular
49 Reduction, Ca and HCO3 transport to shell gland Reduction, Ca and HCO3 transport to shell gland Tissue
447 Reduction, Cholesterol transport in mitochondria Reduction, Cholesterol transport in mitochondria Cellular
78 Reduction, Cumulative fecundity and spawning Reduction, Cumulative fecundity and spawning Individual
106 Reduction, Eggshell thickness Reduction, Eggshell thickness Tissue
129 Reduction, Gonadotropins, circulating concentrations Reduction, Gonadotropins, circulating concentrations Organ
64 Reduction, Ionotropic GABA receptor chloride channel conductance Reduction, Ionotropic GABA receptor chloride channel conductance Cellular
669 Reduction, Neuronal synaptic inhibition Reduction, Neuronal synaptic inhibition Cellular
981 Reduction, NFAT/AP-1 complex formation Reduction, NFAT/AP-1 complex formation Cellular
219 Reduction, Plasma 17beta-estradiol concentrations Reduction, Plasma 17beta-estradiol concentrations Organ
221 Reduction, Plasma vitellogenin concentrations Reduction, Plasma vitellogenin concentrations Organ
243 Reduction, Prostaglandin E2 concentration Reduction, Prostaglandin E2 concentration Tissue
446 Reduction, testosterone level Reduction, testosterone level Tissue
274 Reduction, Testosterone synthesis by ovarian theca cells Reduction, Testosterone synthesis by ovarian theca cells Cellular
413 Reduction, Testosterone synthesis in Leydig cells Reduction, Testosterone synthesis in Leydig cells Cellular
309 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Cellular
285 Reduction, Vitellogenin synthesis in liver Reduction, Vitellogenin synthesis in liver Tissue
1394 Regenerative Proliferation Regenerative Proliferation Cellular
1040 relaxation, smooth muscle relaxation, smooth muscle Tissue
1426 Release of G Proteins Release of G Proteins Cellular
1219 Release of Substance P (SP), Substance P increase in circulation Release of Substance P (SP), Substance P increase in circulation
87 Release, Cytokine Release, Cytokine Cellular
985 Relief, Relief of atopic dermatitis Relief, Relief of atopic dermatitis Individual
1358 Repress, GABA-A receptor Repress, GABA-A receptor Molecular
495 Repressed expression of steroidogenic enzymes Repressed expression of steroidogenic enzymes Cellular
1277 Reproductive failure Reproductive failure Individual
1226 Increased Respiratory irritability and Chronic Cough, Respiratory irritability Organ
397 Response, Keratinocytes Response, Keratinocytes Cellular
1278 ROS formation ROS formation Molecular
927 KE1 : S-Glutathionylation, eNOS S-Glutathionylation, eNOS Molecular
1439 Increased production of pulmonary SAA SAA production increased Molecular
1437 Sensing of the stressor by pulmonary cells Sensing of the stressor Molecular
827 sensitisation, skin sensitisation, skin Organ
1237 Sensitization, Immune system Sensitization, Immune system Individual
1217 Excitation of trigeminal nerves induces Sensory Airway Irritation, Sensory Airway Irritation Organ
1431 Serotonin 1A Receptor Agonism Serotonin 1A Receptor Agonism Molecular
1390 Sexual behavior, decreased Sexual behavior, decreased Individual
417 skewed, sex ratio skewed, sex ratio Population
1222 SP (Substance P) release, Local increase of SP SP (Substance P) release, Local increase of SP Cellular
1460 Increased Substance P (SP) by goblet cells SP release Cellular
1515 spermatocyte depletion spermatocyte depletion Tissue
1068 squamous metaplasia, aberrant basal cells squamous metaplasia, aberrant basal cells Tissue
999 stabilization, co-repressor stabilization, co-repressor
1000 stabilization, PPAR alpha co-repressor stabilization, PPAR alpha co-repressor Molecular
1489 N/A, Steatohepatisis steatohepatitis Organ
650 Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Molecular
456 Suppression, Constitutive androstane receptor, NR1l3 Suppression, Constitutive androstane receptor, NR1l3 Molecular
1046 Suppression, Estrogen receptor (ER) activity Suppression, Estrogen receptor (ER) activity Molecular
461 Suppression, HNF4alpha Suppression, HNF4alpha Molecular
1202 Suppression, IL-2 and IL-4 production Suppression, IL-2 and IL-4 production Cellular
403 Suppression, Immune system Suppression, Immune system Individual
152 Suppression, Inflammatory cytokines Suppression, Inflammatory cytokines Individual
982 Suppression, Suppression in mixed lymphocyte reaction (MLR) Suppression, Suppression in mixed lymphocyte reaction (MLR) Cellular
1203 Suppression, Suppression of production of cytotoxic T-cells Suppression, Suppression of production of cytotoxic T-cells Tissue
1204 Suppression, Suppression of T-cell dependent antibody production Suppression, Suppression of T-cell dependent antibody production Cellular
983 Suppression, Suppression of T-cell dependent antibody response (TDAR) Suppression, Suppression of T-cell dependent antibody response (TDAR) Cellular
450 Suppression, VLDL secretion Suppression, VLDL secretion Cellular
1455 Incudtion, Sustained inflammatory cytokine release Sustained inflammatory cytokine release Molecular
385 Decrease of synaptogenesis Synaptogenesis, Decreased Cellular
89 Synthesis, De Novo FA Synthesis, De Novo FA Cellular
1441 Increased systemic total cholesterol pool Systemic cholesterol increased Organ
280 Thyroxine (T4) in neuronal tissue, Decreased T4 in neuronal tissue, Decreased Organ
281 Thyroxine (T4) in serum, Decreased T4 in serum, Decreased Tissue
1506 testicular toxicity testicular toxicity Organ
1469 Activation, Transforming Growth Factor beta pathway TGFbeta pathway activation Molecular
1468 Activation, Latent Transforming Growth Factor Beta 1 TGFbeta1 activation Molecular
277 Thyroid hormone synthesis, Decreased TH synthesis, Decreased Cellular
974 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12,
975 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12 The binding of FK506 with FKBP12, The binding of FK506 with FKBP12
1462 Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts Thiol protein adducts Molecular
425 Decrease of Thyroidal iodide Thyroidal Iodide, Decreased Cellular
279 Thyroperoxidase, Inhibition Thyroperoxidase, Inhibition Molecular
1492 Tissue resident cell activation Tissue resident cell activation Cellular
1354 Treat, carbamazepine Treat, carbamazepine Molecular
1229 TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ HEK293 fibroblast cells TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ H
1227 TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NEK293 fibroblast cells TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NE
1228 TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary), noncovalently linkked) TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary),
1215 TRPA1 activation, TRPA1 Receptor TRPA1 activation, TRPA1 Receptor Molecular
1230 TRPV1 activation, TRPV1 TRPV1 activation, TRPV1 Molecular
378 Tumorigenesis, Hepatocellular carcinoma Tumorigenesis, Hepatocellular carcinoma Individual
1150 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Impaired function of osteocalcin and MGP Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1138 Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Molecular
932 KE4 : Uncoupling, eNOS Uncoupling, eNOS Cellular
1120 Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form clot Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form cl
1122 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur Tissue
1137 Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form
1168 Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interaction, bone resorption) and glucose and lipid hoemostasis Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interacti
1512 Unfolded Protein Response Unfolded Prortein Response Molecular
1113 Unknown, Unknown,
1114 Unknown, MIE Unknown, MIE Molecular
1129 Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms
1126 Unresolved blood loss, Failure in vascular repair mechanisms Unresolved blood loss, Failure in vascular repair mechanisms
1128 Unresolved hemorrhage, Failure in vascular repair mechanisms Unresolved hemorrhage, Failure in vascular repair mechanisms
470 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Molecular
54 Up Regulation, CD36 Up Regulation, CD36 Molecular
80 Up Regulation, CYP1A1 Up Regulation, CYP1A1 Molecular
84 Up Regulation, CYP1B1 Up Regulation, CYP1B1 Molecular
463 Up Regulation, FAS Up Regulation, FAS Molecular
466 Up Regulation, LDLR (low density lipoprotein receptor) Up Regulation, LDLR (low density lipoprotein receptor) Molecular
462 Up Regulation, SCD-1 Up Regulation, SCD-1 Molecular
1284 Up Regulation, SREBF2 Up Regulation, SREBF2 Cellular
276 Up Regulation, TGFbeta1 expression Up Regulation, TGFbeta1 expression Cellular
1285 Up Regulation, Unsaturated fatty acid Up Regulation, Unsaturated fatty acid Cellular
695 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Molecular
369 Uroporphyria Uroporphyria Individual
1165 Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone proteins e.g., periostin Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone prot
1111 weaj, weaj,
1465 Weak collagen matrix Weak collagen matrix Tissue
1107 Weakened, Colony Weakened, Colony Population